GRI Bio Inc Dossier
Qualitative Analysis
Business overview
GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic, and autoimmune diseases are treated. The company's proprietary platform specializes in developing novel immunotherapies that target and modulate Natural Killer T (NKT) cells, which act as key upstream regulators in the inflammatory cascade. By targeting these cells, GRI Bio's therapies are designed to interrupt disease progression and restore the immune system to homeostasis. The company's lead clinical program is GRI-0621, an oral, small-molecule inhibitor of type 1 invariant NKT (iNKT) cell activity being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Additionally, the company is developing a pipeline of novel type 2 diverse NKT (dNKT) agonists, led by GRI-0803, for autoimmune disorders such as systemic lupus erythematosus (SLE).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the development of lead product candidate GRI-0621, an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells, for the treatment of severe fibrotic lung diseases like Idiopathic Pulmonary Fibrosis (IPF).
Expected impact: Aims to establish a disease-modifying therapy that improves lung function and reduces standard-of-care toxicities.
Progressing GRI-0803, a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells, for the treatment of autoimmune disorders such as Systemic Lupus Erythematosus (SLE).
Expected impact: Expands the clinical pipeline into autoimmune indications and provides a secondary potential revenue stream.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Supports the clinical development of the GRI-0621 program in the United Kingdom.